Correction: Analysis of tyrosine kinase inhibitor-mediated decline in contractile force in rat engineered heart tissue(PLoS ONE (2018)11: 2(e0145937) DOI:10.1371/journal.pone.0145937);Analysis of tyrosine kinase inhibitor-mediated decline in contractile force in rat engineered heart tissue

PLoS ONE

Volumn 11, Issue 2, 2016, Pages

  Jacob, Fabian ^a,b   Yonis, Amina Y ^c   Cuello, Friederike ^a,b   Luther, Pradeep ^c   Schulze, Thomas ^a,b   Eder, Alexandra ^a,b   Streichert, Thomas ^a,e   Mannhardt, Ingra ^a,b   Hirt, Marc N ^a,b   Schaaf, Sebastian ^a,b   Stenzig, Justus ^a,b   Force, Thomas ^d   Eschenhagen, Thomas ^a,b   Hansen, Arne ^a,b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^d TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; LESTAURTINIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; VANDETANIB; CARDIOTOXIN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; AUTOLYSOSOME; AUTOPHAGY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFECT; HEART MUSCLE CELL; MUSCLE FIBER CONTRACTION; NEWBORN; NONHUMAN; RAT; TISSUE ENGINEERING; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIAC MUSCLE CELL; CYTOLOGY; DIAGNOSTIC IMAGING; DRUG EFFECTS; ECHOGRAPHY; FEASIBILITY STUDY; HEART CONTRACTION; LEWIS RAT; PROCEDURES; WISTAR RAT;

ANIMALS; AUTOPHAGY; CARDIOTOXINS; FEASIBILITY STUDIES; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RATS; RATS, INBRED LEW; RATS, WISTAR; TISSUE ENGINEERING; ULTRASONOGRAPHY;

EID: 84959036453     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0208342     Document Type: Erratum

References (29)

1. Laverty H, Benson C, Cartwright E, Cross M, Garland C, Hammond T, et al. How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? Br J Pharmacol. 2011; 163: 675-93. doi: 10.1111/j.1476-5381.2011.01255.x PMID: 21306581
2. Cross MJ, Berridge BR, Clements PJ, Cove-Smith L, Force TL, Hoffmann P, et al. Physiological, pharmacological and toxicological considerations of drug-induced structural cardiac injury. Br J Pharmacol. 2015; 172: 957-74. doi: 10.1111/bph.12979 PMID: 25302413
3. Cheng H, Force T. Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ Res. 2010; 106: 21-34. doi: 10.1161/CIRCRESAHA.109.206920 PMID: 20056943
4. Kerkelä R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006; 12: 908-16. doi: 10.1038/nm1446 PMID: 16862153
5. Dyck JRB, Lopaschuk GD. AMPK alterations in cardiac physiology and pathology: enemy or ally? J Physiol. 2006; 574: 95-112. doi: 10.1113/jphysiol.2006.109389 PMID: 16690706
6. Herman EH, Knapton A, Rosen E, Thompson K, Rosenzweig B, Estis J, et al. A multifaceted evaluation of imatinib-induced cardiotoxicity in the rat. Toxicol Pathol. 2011; 39: 1091-106. doi: 10.1177/0192623311419524 PMID: 21937741
7. Kerkela R, Woulfe KC, Durand J, Vagnozzi R, Kramer D, Chu TF, et al. Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin Transl Sci. 2009; 2: 15-25. doi: 10.1111/j.1752-8062.2008.00090.x PMID: 20376335
8. Cheng H, Kari G, Dicker AP, Rodeck U, Koch WJ, Force T. A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity. Circ Res. 2011; 109: 1401-9. doi: 10.1161/CIRCRESAHA.111.255695 PMID: 21998323
9. Holen I, Stromhaug PE, Gordon PB, Fengsrud M, Berg TO, Seglen PO. Inhibition of autophagy and multiple steps in asialoglycoprotein endocytosis by inhibitors of tyrosine protein kinases (tyrphostins). J Biol Chem. 1995; 270: 12823-12831. doi: 10.1074/jbc.270.21.12823 PMID: 7759538
10. French KJ, Coatney RW, Renninger JP, Hu CX, Gales TL, Zhao S, et al. Differences in effects on myocardium and mitochondria by angiogenic inhibitors suggest separate mechanisms of cardiotoxicity. Toxicol Pathol. 2010; 38: 691-702. doi: 10.1177/0192623310373775 PMID: 20616376
11. Hansen A, Eder A, Bönstrup M, Flato M, Mewe M, Schaaf S, et al. Development of a Drug Screening Platform Based on Engineered Heart Tissue. Circ Res. 2010; 107: 35-44. doi: 10.1161/CIRCRESAHA. 109.211458 PMID: 20448218
12. Schaaf S, Shibamiya A, Mewe M, Eder A, Stöhr A, Hirt MN, et al. Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology. de Windt LJ, editor. PLoS One. 2011; 6: e26397. doi: 10.1371/journal.pone.0026397 PMID: 22028871
13. Hirt MN, Sörensen NA, Bartholdt LM, Boeddinghaus J, Schaaf S, Eder A, et al. Increased afterload induces pathological cardiac hypertrophy: a new in vitro model. Basic Res Cardiol. 2012; 107: 307. doi: 10.1007/s00395-012-0307-z PMID: 23099820
14. Eder A, Hansen A, Uebeler J, Schulze T, Neuber C, Schaaf S, et al. Effects of proarrhythmic drugs on relaxation time and beating pattern in rat engineered heart tissue. Basic Res Cardiol. 2014; 109: 436. doi: 10.1007/s00395-014-0436-7 PMID: 25209140
15. Pegram M, Ngo D. Application and potential limitations of animal models utilized in the development of trastuzumab (Herceptin): A case study. Advanced Drug Delivery Reviews. 2006. pp. 723-734. doi: 10.1016/j.addr.2006.05.003 PMID: 16876287
16. Will Y, Dykens J a, Nadanaciva S, Hirakawa B, Jamieson J, Marroquin LD, et al. Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells. Toxicol Sci. 2008; 106: 153-61. doi: 10.1093/toxsci/kfn157 PMID: 18664550
17. Rana P, Anson B, Engle S, Will Y. Characterization of human-induced pluripotent stem cell-derived cardiomyocytes: bioenergetics and utilization in safety screening. Toxicol Sci. 2012; 130: 117-31. doi: 10.1093/toxsci/kfs233 PMID: 22843568
18. Abi-Gerges N, Pointon A, Pullen GF, Morton MJ, Oldman KL, Armstrong D, et al. Preservation of cardiomyocytes from the adult heart. J Mol Cell Cardiol. Elsevier Ltd; 2013; 64: 108-19. doi: 10.1016/j. yjmcc.2013.09.004 PMID: 24051370
19. Long X, Boluyt MO, Hipolito ML, Lundberg MS, Zheng JS, O'Neill L, et al. P53 and the Hypoxia-Induced Apoptosis of Cultured Neonatal Rat Cardiac Myocytes. J Clin Invest. 1997; 99: 2635-43. doi: 10.1172/JCI119452 PMID: 9169493
20. Hirt MN, Boeddinghaus J, Mitchell A, Schaaf S, Börnchen C, Müller C, et al. Functional improvement and maturation of rat and human engineered heart tissue by chronic electrical stimulation. J Mol Cell Cardiol. Elsevier B.V.; 2014; 74: 151-61. doi: 10.1016/j.yjmcc.2014.05.009 PMID: 24852842
21. Zhao Y, Xue T, Yang X, Zhu H, Ding X, Lou L, et al. Autophagy plays an important role in sunitinib-mediated cell death in H9c2 cardiac muscle cells. Toxicol Appl Pharmacol. Elsevier Inc.; 2010; 248: 20-7. doi: 10.1016/j.taap.2010.07.007 PMID: 20637791
22. Kharaziha P, De Raeve H, Fristedt C, Li Q, Gruber A, Johnsson P, et al. Sorafenib has potent antitumor activity against multiple myeloma In Vitro, Ex Vivo, and In Vivo in the 5T33MM mouse model. Cancer Res. 2012; 72: 5348-5362. doi: 10.1158/0008-5472.CAN-12-0658 PMID: 22952216
23. Shimgu T, Fujiwara K, Bogler O, Akiyama Y, Meritake K, Shinojima N, et al. Inhibition of autophagy at a late stage enhances imatinib-induced cytotoxicity In human malignant glioma cells. Int J Cancer. 2009; 124: 1060-1071. doi: 10.1002/ijc.24030 PMID: 19048625
24. Bellodi C, Lidonnici MR, Hamilton A, Helgason GV, Soliera AR, Ronchetti M, et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest. 2009; 119: 1109-1123. doi: 10.1172/JCI35660 PMID: 19363292
25. Ikeda T, Ishii K a, Saito Y, Miura M, Otagiri a, Kawakami Y, et al. Inhibition of autophagy enhances sunitinib-induced cytotoxicity in rat pheochromocytoma PC12 cells. J Pharmacol Sci. 2013; 121: 67-73. doi: 10.1254/jphs.12158FP PMID: 23269235
26. Shimizu S, Takehara T, Hikita H, Kodama T, Tsunematsu H, Miyagi T, et al. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. Int J Cancer. 2012; 131: 548-557. doi: 10.1002/ijc.26374 PMID: 21858812
27. Hu W, Lu S, McAlpine I, Jamieson JD, Lee DU, Marroquin LD, et al. Mechanistic investigation of imatinib-induced cardiac toxicity and the involvement of c-Abl kinase. Toxicol Sci. 2012; 129: 188-99. doi: 10.1093/toxsci/kfs192 PMID: 22641616
28. Hill JA. Autophagy in cardiac plasticity and disease. Pediatr Cardiol. 2011; 32: 282-9. doi: 10.1007/s00246-010-9883-6 PMID: 21249349
29. Kubli D a, Gustafsson ÅB. Mitochondria and mitophagy: the yin and yang of cell death control. Circ Res. 2012; 111: 1208-21. doi: 10.1161/CIRCRESAHA.112.265819 PMID: 23065344